7UK Prospective Diabetes Study(UKPDS) Group. Intensive blood -glucose control with sulhonylurcas or insulin compared with conventional treatment and risk of complications in patients with type 2diabetes ( UKPDS33 ) lancet 1998 ;352 (9,131) :837 - 853.
8Zavaroni I, Bonora E, Pagliara M, ct al, Riskfactors for coronary atery disease in healthy persons with hyperinsulinemia and normal glucose tolerance NEnglJMed 1989 ;320 ;702 - 706.
9UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovasular and microvaslular complications in type 2diabetes:UKPDS38. BMJ 1998;317:703 -713.
10Golberg RB, Mellies MJ, Sacks FM, et al, Cardiovascular events and their reduction with pravastatin in diabetic and glucose - intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events(CARE) trial. The Care Investigators. Circulation 1998 ;98:2513 - 2519.
1Chen C J,Kuo T,Tseng Y,et a1.Combined cardiacsympathetic excitation and vagal impairment in patientswith on organic erectile dysfunetion [J].ClinNeurophysiol,2009,120(2): 348-352.
2Stellato R K,Feldmam H A,Hamdy O,et a1.Testosterone,sex hormone-binding globulin,and the development oftype 2 diabetes in middle-aged men: prospective resultsfrom the Massachusetts male aging study [J].DiabetesCare,2000.23: 490-494.
3Malavige L S,Levy J C.Erectile dysfunction in diabetesmellitus [J].J Sex Med,2009,6(5): 1232-1247.
4Goldstein I,Young J M,Fischer J,et a1.Vardenafil,anew phosphodiesterase type 5 inhibitor,in the treatmentof erectile dysfunction in men with diabetes: a multicenterdouble blind placebo controlled fixed dose study [J].Diabetes Care,2003,26(3): 777-783.
